Skip to main content
SpringerLink
Log in

Morbus Parkinson

Wann sind Pflaster, Pens oder Pumpen eine sinnvolle Ergänzung zur oralen Therapie?

  • zertifizierte fortbildung
  • Published:
InFo Neurologie & Psychiatrie Aims and scope

Zusammenfassung

Bei der Parkinson-Erkrankung treten unter dopaminerger Therapie nach einigen Jahren Wirkfluktuationen in Form von kurzen Wearing-OFF-Phasen auf. Später können längere OFF-Phasen und Dyskinesien hinzukommen und nach zehn Jahren bestehen ausgeprägte Wirkschwankungen. Parenteral applizierbare Therapeutika wie Rotigotin-Pflaster, Apomorphin-Pen und -Pumpe sowie L-Dopa-Pumpen können hier eine sinnvolle Ergänzung und Fortführung der oralen medikamentösen Therapie sein.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1
2
3
4
5

Literatur

  1. Tolosa E, Marti MJ, Valldeoriola F, Molinuevo JL. History of levodopa and dopamine agonists in Parkinson’s disease treatment. Neurology. 1998 Jun;50(6 Suppl 6):S2–10; discussion S44-8. PubMed PMID: 9633679.

    Article  CAS  PubMed  Google Scholar 

  2. Setter SM. Assessing the impact of ease of administration and tolerability on treatment choices in Parkinson’s disease. Neurologic clinics. 2008 Aug;26(3 Suppl):S45–63, vi. PubMed PMID: 18774442.

    Article  PubMed  Google Scholar 

  3. Grosset KA, Reid JL, Grosset DG. Medicine-taking behavior: implications of suboptimal compliance in Parkinson’s disease. Mov Disord. 2005 Nov;20(11):1397–404. PubMed PMID: 16092116.

    Article  PubMed  Google Scholar 

  4. Grosset D, Antonini A, Canesi M, Pezzoli G, Lees A, Shaw K, et al. Adherence to antiparkinson medication in a multicenter European study. Mov Disord. 2009 Apr 30;24(6):826–32. PubMed PMID: 19191340.

    Article  PubMed  Google Scholar 

  5. LeWitt PA, Boroojerdi B, MacMahon D, Patton J, Jankovic J. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. Clin Neuropharmacol. 2007 Sep-Oct;30(5):256–65. PubMed PMID: 17909303.

    Article  CAS  PubMed  Google Scholar 

  6. LeWitt PA, Lyons KE, Pahwa R, Group SPS. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology. 2007 Apr 17;68(16):1262–7. Pub-Med PMID: 17438216.

    Article  CAS  PubMed  Google Scholar 

  7. Zhou CQ, Li SS, Chen ZM, Li FQ, Lei P, Peng GG. Rotigotine transdermal patch in Parkinson’s disease: a systematic review and meta-analysis. PLoS One. 2013;8(7):e69738. Pub-Med PMID: 23936090. Pubmed Central PMCID: 3720658.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  8. Apomorphin. Akt Neurol 2011;38: S1. Thieme.

  9. Deleu D, Hanssens Y, Northway MG. Subcutaneous apomorphine: an evidence-based review of its use in Parkinson’s disease. Drugs & aging. 2004;21(11):687–709. PubMed PMID: 15323576.

    Article  CAS  Google Scholar 

  10. Ostergaard L, Werdelin L, Odin P, Lindvall O, Dupont E, Christensen PB, et al. Pen injected apomorphine against off phenomena in late Parkinson’s disease: a double blind, placebo controlled study. Journal of neurology, neurosurgery, and psychiatry. 1995 Jun;58(6):681–7. PubMed PMID: 7608665. Pubmed Central PMCID: 1073544.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson’s disease: a long term follow up. Journal of neurology, neurosurgery, and psychiatry. 1998 Nov;65(5):709–16. PubMed PMID: 9810943. Pubmed Central PMCID: 2170363.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  12. Hagell P, Odin P. Apomorphine in the treatment of Parkinson’s disease. The Journal of neuroscience nursing: journal of the American Association of Neuroscience Nurses. 2001 Feb;33(1):21–34, 7-8. PubMed PMID: 11233359.

    Article  CAS  Google Scholar 

  13. Poewe W, Kleedorfer B, Wagner M, Benke T, Gasser T, Oertel W. Side-effects of subcutaneous apomorphine in Parkinson’s disease. Lancet. 1989 May 13;1(8646):1084–5. PubMed PMID: 2566037.

    Article  CAS  PubMed  Google Scholar 

  14. Pollak P, Champay AS, Gaio JM, Hommel M, Benabid AL, Perret J. [Subcutaneous administration of apomorphine in motor fluctuations in Parkinson’s disease]. Revue neurologique. 1990;146(2):116–22. PubMed PMID: 2320817. Administration sous-cutanee d’apomorphine dans les fluctuations motrices de la maladie de Parkinson.

    CAS  PubMed  Google Scholar 

  15. Kempster PA, Iansek R, Larmour I. Intermittent subcutaneous apomorphine injection treatment for parkinsonian motor oscillations. Australian and New Zealand journal of medicine. 1991 Jun;21(3):314–8. PubMed PMID: 1953509.

    Article  CAS  PubMed  Google Scholar 

  16. Hughes AJ, Bishop S, Kleedorfer B, Turjanski N, Fernandez W, Lees AJ, et al. Subcutaneous apomorphine in Parkinson’s disease: response to chronic administration for up to five years. Mov Disord. 1993 Apr;8(2):165–70. PubMed PMID: 8474483.

    Article  CAS  PubMed  Google Scholar 

  17. Merello M, Leiguarda R. [Treatment of motor fluctuations in Parkinson’s disease with subcutaneous injections of apomorphine]. Medicina. 1995;55(1):5–10. PubMed PMID: 7565037. Tratamiento de las fluctuaciones motoras de la enfermedad de Parkinson con inyecciones subcutaneas de apomorfina.

    CAS  PubMed  Google Scholar 

  18. Dewey RB, Jr., Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Archives of neurology. 2001 Sep;58(9):1385–92. PubMed PMID: 11559309.

    Article  PubMed  Google Scholar 

  19. Lees AJ. Dopamine agonists in Parkinson’s disease: a look at apomorphine. Fundamental & clinical pharmacology. 1993;7(3–4):121–8. PubMed PMID: 8500783.

    Article  CAS  Google Scholar 

  20. Tyne HL, Parsons J, Sinnott A, Fox SH, Fletcher NA, Steiger MJ. A 10 year retrospective audit of long-term apomorphine use in Parkinson’s disease. Journal of neurology. 2004 Nov;251(11):1370–4. PubMed PMID: 15592733.

    Article  PubMed  Google Scholar 

  21. Pollak P, Champay AS, Hommel M, Perret JE, Benabid AL. Subcutaneous apomorphine in Parkinson’s disease. Journal of neurology, neurosurgery, and psychiatry. 1989 Apr;52(4):544. PubMed PMID: 2738604. Pubmed Central PMCID: 1032319.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Gancher ST, Nutt JG, Woodward WR. Apomorphine infusional therapy in Parkinson’s disease: clinical utility and lack of tolerance. Mov Disord. 1995 Jan;10(1):37–43. PubMed PMID: 7885354.

    Article  CAS  PubMed  Google Scholar 

  23. Kanovsky P, Kubova D, Bares M, Hortova H, Streitova H, Rektor I, et al. Levodopa-induced dyskinesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up. Mov Disord. 2002 Jan;17(1):188–91. PubMed PMID: 11835461.

    Article  PubMed  Google Scholar 

  24. Manson AJ, Turner K, Lees AJ. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson’s disease: long-term follow-up study of 64 patients. Mov Disord. 2002 Nov;17(6):1235–41. PubMed PMID: 12465062.

    Article  PubMed  Google Scholar 

  25. Martinez-Martin P, Reddy P, Antonini A, Henriksen T, Katzenschlager R, Odin P, et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson’s disease compared to conventional therapy: a real life study of non motor effect. J Parkinsons Dis. 2011;1(2):197–203. PubMed PMID: 23934921.

    CAS  PubMed  Google Scholar 

  26. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease. The New England journal of medicine. 2001 Sep 27;345(13):956-63. PubMed PMID: 11575287.

  27. Nyholm D. Duodopa(R) treatment for advanced Parkinson’s disease: a review of efficacy and safety. Parkinsonism & related disorders. 2012 Sep;18(8):916–29. PubMed PMID: 22824056.

    Article  Google Scholar 

  28. Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet neurology. 2014 Feb;13(2):141–9. PubMed PMID: 24361112.

    Article  CAS  Google Scholar 

  29. Antonini A, Isaias IU, Canesi M, Zibetti M, Mancini F, Manfredi L, et al. Duodenal levodopa infusion for advanced Parkinson’s disease: 12-month treatment outcome. Mov Disord. 2007 Jun 15;22(8):1145–9. PubMed PMID: 17661426.

    Article  PubMed  Google Scholar 

  30. Eggert K, Schrader C, Hahn M, Stamelou M, Russmann A, Dengler R, et al. Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol. 2008 May-Jun;31(3):151–66. PubMed PMID: 18520982.

    Article  CAS  PubMed  Google Scholar 

  31. Fernandez HH, Vanagunas A, Odin P, Espay AJ, Hauser RA, Standaert DG, et al. Levodopa-carbidopa intestinal gel in advanced Parkinson’s disease open-label study: interim results. Parkinsonism & related disorders. 2013 Mar;19(3):339–45. PubMed PMID: 23287001. Pubmed Central PMCID: 3661282.

    Article  Google Scholar 

  32. Devos D, French DSG. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson’s disease. Mov Disord. 2009 May 15;24(7):993–1000. PubMed PMID: 19253412.

    Article  PubMed  Google Scholar 

  33. Urban PP, Wellach I, Faiss S, Layer P, Rosenkranz T, Knop K, et al. Subacute axonal neuropathy in Parkinson’s disease with cobalamin and vitamin B6 deficiency under duodopa therapy. Mov Disord. 2010 Aug 15;25(11):1748–52. PubMed PMID: 20740570.

    Article  PubMed  Google Scholar 

  34. Uncini A, Eleopra R, Onofrj M. Polyneuropathy associated with duodenal infusion of levodopa in Parkinson’s disease: features, pathogenesis and management. Journal of neurology, neurosurgery, and psychiatry. 2014 Aug 28. Pub-Med PMID: 25168395.

  35. Lehnerer SM, Fietzek UM, Messner M, Ceballos-Baumann AO. Subacute peripheral neuropathy under duodopa therapy without cobalamin deficiency and despite supplementation. J Neural Transm. 2014 Oct;121(10):1269–72. PubMed PMID: 24710647.

    Article  CAS  PubMed  Google Scholar 

  36. Merola A, Zibetti M, Rizzone MG, Troiano M, Artusi CA, Angrisano S, et al. Prospective assessment of peripheral neuropathy in Duodopa-treated parkinsonian patients. Acta Neurol Scand. 2014 Jan;129(1):e1–5. PubMed PMID: 23834498.

    Article  CAS  PubMed  Google Scholar 

  37. Doppler K, Ebert S, Uceyler N, Trenkwalder C, Ebentheuer J, Volkmann J, et al. Cutaneous neuropathy in Parkinson’s disease: a window into brain pathology. Acta neuropathologica. 2014 Jul;128(1):99–109. PubMed PMID: 24788821. Pubmed Central PMCID: 4059960.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Neurologie, Universitätsklinikum Eppendorf, Martinistrasse 52, 20246, Hamburg, Deutschland

    Monika Pötter-Nerger, Peter Ludewig, Ute Hidding, Ines Goerendt, Christian Gerloff & Carsten Buhmann

Authors
  1. Monika Pötter-Nerger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter Ludewig
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ute Hidding
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ines Goerendt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christian Gerloff
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Carsten Buhmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Monika Pötter-Nerger.

Additional information

Interessenkonflikt

Die Autoren erklären, dass sie sich bei der Erstellung des Beitrags von keinen wirtschaftlichen Interessen leiten ließen. M. Pötter-Nerger erklärt die geplante Teilnahme an einer Studie zum Einsatz des Apomorphin-Pens bei Morbus Parkinson in 2015. C. Buhmann ist ge legentlich als Referent und/oder Berater für Medtonic, Orion Pharma, TEVA, und UCB tätig. Werbung in dieser Zeitschriftenausgabe hat keinen Bezug zur CME-Fortbildung. Der Verlag garantiert, dass die CME-Fortbildung sowie die CME-Fragen frei sind von werblichen Aussagen und keinerlei Produktempfehlungen enthalten. Dies gilt insbesondere für Präparate, die zur Therapie des dargestellten Krankheits bildes geeignet sind.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pötter-Nerger, M., Ludewig, P., Hidding, U. et al. Wann sind Pflaster, Pens oder Pumpen eine sinnvolle Ergänzung zur oralen Therapie?. InFo Neurologie 16, 42–53 (2014). https://doi.org/10.1007/s15005-014-1062-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15005-014-1062-5

Search

Navigation